By Ethan Covey
Dolutegravir-lamivudine (DTG/3TC; Dovato, ViiV Healthcare) demonstrates high rates of virologic suppression among people living with HIV and who have reactive anti–hepatitis B core antibody (anti-HBc) and no evidence of active hepatitis B virus (HBV) infection, according to data presented at AIDS 2024, held in Munich (abstract OAB0106LB).
The high virologic suppression is comparable to that found with three- or four-drug comparator regimens.